Kenvue Nicorette®* Products Added To World Health Organization's Tobacco Cessation Pre-Qualification List
Date
7/17/2024 3:32:52 AM
(MENAFN- Mid-East)
Dubai, UAE, July, 2024: On Tuesday, July 2, the World health Organization (WHO) released the first ever clinical treatment guidelines for tobacco cessation for adults. The guidelines focus on helping the more than 750 million tobacco users who want to quit all forms of tobacco.
These new guidelines share that“combining pharmacotherapy with behavioural interventions significantly increases quitting success rates.” Among the recommendations is Nicotine Replacement Therapy (NRT): using products - like Nicorette® patches, gums, lozenge and mouth sprays - for tobacco cessation.
Nearly a quarter of the global population uses tobacco, including approximately 61 million people in the Middle East.[1]
Kenvue's Nicorette® gum and patch are the first nicotine replacement therapies (NRTs) to be added to the WHO's pre-qualification list, which assesses the quality, safety, and efficacy of medicinal products. The WHO's pre-qualification list is intended to guide UN agencies and other international organizations on the quality of medicines in high priority therapeutic areas, notably for supply to low-income countries. NRT lozenge, oral spray, patch, and gum are also included on the WHO Model List of Essential Medicines (EML).
Since October 2022, Kenvue has been an active member of the WHO's Tobacco Cessation Consortium. The Consortium is a group of partners in the private and public sectors (including Tech, Consumer Health/Pharma, and NGOs) to help people access essential cessation support and treatment to deal with tobacco dependence.
Tobacco remains one of the world's biggest public health challenges, killing more than 8 million people a year.[2] Kenvue and Nicorette® are committed to making smoking cessation support and treatment available to more people and we are proud to be a part of creating a world free from tobacco and nicotine.
About Kenvue:
Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Nicorette®, Aveeno®, Listerine®, Neutrogena®, and Johnson's® Baby are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary power of everyday care and our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes.
MENAFN17072024005446012082ID1108448528
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.